Global pharmaceutical companies Genentech, Biogen and Hoffmann-La Roche filed a patent infringement lawsuit against Dr. Reddy's Laboratories in federal court Friday alleging the defendants plan to release a "copycat" of Rituxan, their rheumatoid arthritis and non-Hodgkin lymphoma-treating medication.

This complaint was first surfaced by Law.com Radar.

The suit, Genentech v. Dr. Reddy's Laboratories, was filed on behalf of the plaintiff pharmaceutical companies by attorneys with Orrick Herrington & Sutcliffe and McCarter & English in U.S. District Court for the District of New Jersey. The 30-count complaint seeks declaratory relief for the defendants' alleged infringement on patents related to their planned release of a biosimilar drug, according to the complaint.